KYBELLA Drug Patent Profile

Which patents cover Kybella, and when can generic versions of Kybella launch?

Kybella is a drug marketed by Abbvie and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries.

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deoxycholic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kybella

A generic version of KYBELLA was approved as deoxycholic acid by WILSHIRE PHARMS INC on April 2^nd, 2021.

Summary for KYBELLA

International Patents:	146
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	17
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KYBELLA
What excipients (inactive ingredients) are in KYBELLA?	KYBELLA excipients list
DailyMed Link:	KYBELLA at DailyMed

Recent Clinical Trials for KYBELLA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Glonova Pharma Co., Ltd	PHASE1
T-TOP Clinical Research Co., Ltd.	PHASE1
AbbVie	PHASE4

See all KYBELLA clinical trials

Pharmacology for KYBELLA

Drug Class	Cytolytic Agent
Physiological Effect	Decreased Cell Membrane Integrity

Paragraph IV (Patent) Challenges for KYBELLA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KYBELLA	Injection	deoxycholic acid	10 mg/mL (2 mL)	206333	1	2018-07-13

US Patents and Regulatory Information for KYBELLA

KYBELLA is protected by fourteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	7,754,230
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	8,546,367		Y
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	12,161,653

Expired US Patents for KYBELLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	8,298,556
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	8,846,066

International Patents for KYBELLA

When does loss-of-exclusivity occur for KYBELLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

New Zealand

Philippines

Poland

Portugal

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KYBELLA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2827643
European Patent Office	2675460
Mexico	2013009559

Supplementary Protection Certificates for KYBELLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758590	PA2017006	Lithuania		PRODUCT NAME: DEZOKSICHOLIO RUGSTIES NATRIO DRUSKA; REGISTRATION NO/DATE: LT/1/16/3960/001 20160909
1758590	300907	Netherlands		PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT; REGISTRATION NO/DATE: RVG120593 20170804
1758590	CA 2017 00067	Denmark		PRODUCT NAME: DEOXYCHOLSYRE NATRIUMSALT; NAT. REG. NO/DATE: 59040 20170703; FIRST REG. NO/DATE: IS IS/1/16/071/01 20160729

KYBELLA (deoxycholic acid) market dynamics and financial trajectory: pricing, demand, exclusivity, competition, and earnings exposure

Last updated: July 21, 2026

Kybella (deoxycholic acid) is a marketed injectable for submental fat reduction. Its commercial trajectory is shaped by (1) a limited but persistent demand base tied to dermatology/plastic surgery practice patterns, (2) payer leverage and dose-cost pressure because treatment requires multiple vials per session series, and (3) competitive threats from no-direct-substitute modalities and from off-label substitution that has reduced addressable volume growth. Financial impact is dominated by product life-cycle maturity, inventory and manufacturing ramp effects early on, and later by pricing and mix rather than material unit growth.

FDA approval, label scope, and dosing dynamics

• Indication: localized moderate-to-severe submental fat in adults as an aesthetic procedure.
• Treatment pattern: fixed injection visits with repeated dosing over a treatment series; the number of vials and visits depends on baseline fat volume and response.
• Commercial implication: revenue is constrained by per-patient total dose intensity, clinic capacity limits, and reimbursement denials or carve-outs for cosmetic positioning.

What market dynamics drive KYBELLA sales volume and revenue per patient?

Key demand drivers

1. Procedure-based adoption: Kybella is administered in-office via injection by trained clinicians. Demand tracks “aesthetic capacity” and scheduling throughput more than prescription refill behavior.
2. Clinician familiarity and practice standardization: Early adoption created a cohort of practices that continue using Kybella for appropriate candidates. Once a local standard forms, switching is less frequent unless price or outcomes shift.
3. Payer stance for cosmetic-adjacent indications: Even with FDA labeling, submental fat reduction can face coverage limits. This converts volume growth into a combination of (a) cash pay and (b) selective payer coverage, both sensitive to pricing.
4. Patient response variability: Treatment involves multiple sessions. Patients who stop early or require additional visits influence dose intensity, which affects revenue per treated case.

Pricing and dose-intensity mechanics

• Kybella pricing is tightly coupled to vials per treatment series. Revenue changes can occur without large unit changes if:
  • average vial utilization per responder increases, or
  • payers force lower adherence, reducing the number of sessions completed.

Substitution and indirect competition

• There is no direct molecular substitute with identical mechanism and label. Practical competition comes from:
  • device-based body contouring (noninjection)
  • other injectables and tightening modalities used off-label or for overlapping cosmetic outcomes
  • clinician preference shifts based on session burden and adverse event profiles

How does KYBELLA’s financial trajectory look across its product life cycle?

Trajectory pattern typical of in-office injectables

• Launch: revenue growth supported by label awareness, payer education, and initial clinician adoption.
• Mid-life: plateauing as growth in eligible patients slows and competitive modalities mature.
• Mature phase: revenue becomes more sensitive to pricing actions, promotional spend, vial utilization, and patient conversion rather than raw prescription starts.

What matters most to financials for Kybella

1. Net sales per vial and average dosing
   • Any decline in average vials per treated patient reduces revenue even if treated patients stay constant.
2. Realized reimbursement and channel mix
   • Shifts toward cash-pay can stabilize revenue. Shifts toward restrictive coverage reduce effective demand.
3. Manufacturing and supply stability
   • In-office injectables have less buffering than chronic drugs. Stock timing can limit clinic utilization and delay procedure capture.

Ownership and commercial footprint

• Kybella is marketed by AbbVie Inc. (commercial partner structure depends on agreement terms for the product portfolio). The market’s financial narrative is therefore tied to AbbVie’s dermatology/aesthetics contribution versus broader immunology and oncology offsets.

When does KYBELLA lose exclusivity, and what drives timeline risk for revenue?

Exclusivity categories that typically matter

• Regulatory exclusivity (New Chemical Entity, brand exclusivity, pediatric exclusivity where applicable): affects the timing of generic ability to file or market, depending on what is still protected.
• Patent exclusivity (composition, formulation, method-of-use): often controls actual competitive entry even when regulatory exclusivity expires.

Commercial relevance

• The closer the product is to patent expiry, the more pipeline and payer planning can change.
• For an injection used in elective aesthetics, any competitive entry that offers materially lower acquisition cost can increase clinic willingness to adopt and sustain higher-volume cycles.

What patents protect KYBELLA, and how strong is the patent estate?

Patent estate review approach used for litigation and entry risk

• Composition of matter: direct molecule protection and salt/complex protection.
• Formulation: concentration, excipients, and stability claims.
• Method-of-use: specific injection protocols, treatment cycles, and dosing schemes.

Featured snippet answer

• Kybella’s patent strength is evaluated primarily through composition/formulation and method-of-use coverage, because generic entry typically needs an argument that it can market without infringing those claims.

Entry barrier implications

• Even if a generic product is approved through an abbreviated pathway, launch and sustained market share depend on whether the company is cleared of patent infringement exposure (or settles on carve-outs, launch timing, or design-around).

Note: Patent numbers and expiration dates cannot be reliably enumerated here without an Orange Book patent list or specific court docket data for the relevant KYBELLA NDA.

What is the Orange Book status of KYBELLA, and what listings matter for generics?

What to look for

• NDA-specific Orange Book entries for:
  • active ingredient (deoxycholic acid)
  • dosage form (injection)
  • each patent’s type (composition, method, formulation)
  • expiration dates and patent status

Why it matters

• Orange Book listings drive:
  • Paragraph IV filing decisions
  • settlement leverage
  • launch design-around strategies

Note: A precise Orange Book table (patent numbers, claim types, and dates) cannot be produced without the Orange Book listing details.

Have generics or biosimilars challenged KYBELLA via Paragraph IV, and what is the litigation history?

Kybella is a small-molecule drug product, so biosimilar litigation is not the relevant category. Competitive entry risks would come through ANDA (generic) routes, typically supported by Paragraph IV certifications against Orange Book patents.

What litigation outcomes usually do to financials

• A favorable court or settlement can move launch dates forward, compressing branded net sales.
• An adverse ruling can sustain exclusivity and defer generic erosion, allowing the brand to manage pricing and supply.

Note: Specific Paragraph IV dockets, case numbers, and settlement terms cannot be provided here without docket and Orange Book listing details.

How does KYBELLA compare with competing submental fat treatments on commercial adoption and payer fit?

Competition map (non-direct)

• Energy-based or ultrasound-based tightening and fat reduction devices
• Injectables with overlapping cosmetic contouring objectives
• Off-label use of approved injectables for contouring outcomes

Adoption economics

• Kybella’s clinic adoption depends on:
  • procedure time per treatment
  • total visit burden and staff coordination
  • predictable outcome distribution
  • adverse event management and patient counseling cost

Payer fit

• Cosmetic-adjacent positioning limits coverage consistency.
• Competitors offering evidence for overlapping indications under different billing codes may have different reimbursement dynamics that shift demand.

What generic entry risks exist for KYBELLA, and how would launch scenarios affect AbbVie revenue?

Scenario framework used by commercial planners

1. No entry or delayed entry
   • Brand maintains moat from clinical practice patterns and supply control.
2. Single generic entry with limited formulary placement
   • Sales erosion is partial; net sales decline can be smaller if cash-pay and cash-insurance mix remains.
3. Multiple entrants with aggressive pricing and broad pharmacy/clinic adoption
   • Larger acquisition cost reductions can cause faster replacement and steeper branded net sales compression.

Revenue sensitivity factors

• Total addressable “treated cases” in aesthetics often grows slowly; market share gains require either:
  • conversion of patients from alternative modalities, or
  • payer shifts enabling coverage.
• If generic price drops are substantial, clinics can scale up, but only if competition does not reduce outcomes or increase adverse event rates.

Note: Concrete launch timing and number of likely entrants require Orange Book and Paragraph IV history.

What formulation, dosing, or method-of-use patents could constrain generic design-around for KYBELLA?

Generic design-around pressure points

• Injection concentration and stabilized formulation claims
• Stability and manufacturing process claims that limit ability to match the reference product
• Method-of-use claims tied to:
  • number of treatment sessions
  • injection placement and volume per site
  • response assessment thresholds

How this affects litigation leverage

• If method-of-use claims are broad, generic sponsors may face either:
  • infringement risk if they market identical instruction sets, or
  • need to alter labeling, which can be hard to implement if it undermines prescriber adoption.

Note: Specific claim language and coverage scope cannot be listed without enumerating the relevant patents.

What FDA regulatory milestones shape KYBELLA’s ability to maintain market share?

Regulatory milestones with direct commercial impact

• Supplement approvals that change dosing guidance, labeling, or manufacturing updates can influence:
  • prescriber comfort
  • adverse event risk perception
  • payer comfort with guideline-based use
• Safety communications can temporarily slow adoption.
• Manufacturing approvals and stability updates reduce supply disruption risk.

Note: Specific FDA supplements, dates, and labeling revisions are not included here.

What commercial strategies have historically sustained KYBELLA performance?

Brand tactics consistent with in-office aesthetics products

• Clinician education on patient selection and dosing optimization to improve outcomes and retention through the full treatment series.
• Controlled distribution and clinic supply planning to minimize appointment delays.
• Pricing and contracting strategies aligned to payer coverage realities and cash-pay demand elasticity.

Mix management

• Because patients are treated in series, small changes in conversion rate from consultation to completed protocol can drive material revenue changes.

Key takeaways

• Kybella’s market dynamics are dominated by treatment-series dose intensity, elective procedure demand, and payer coverage constraints rather than repeat dispensing.
• Financial trajectory typically follows launch adoption, then maturity with pricing and utilization as the main levers.
• Generic and litigation risk depends on the Orange Book patent list and Paragraph IV history; method-of-use and formulation claims can be launch blockers even for small-molecule ANDAs.
• The competitive landscape is indirect: noninjection modalities and overlapping contouring solutions shift demand based on convenience, cost, and outcomes.

FAQs

1. Does KYBELLA have direct molecular competitors with identical FDA indications?
2. How does the number of treatment sessions influence KYBELLA net sales per treated patient?
3. What types of patents (composition vs method-of-use) most often delay generic launch for in-office injectables?
4. How do payer denials for cosmetic-adjacent indications typically impact brand net sales for submental fat products?
5. What manufacturing or supply disruptions most affect clinic procedure scheduling for KYBELLA?

References

1. FDA Orange Book. (accessed via FDA databases; specific KYBELLA listing not reproduced here).
2. FDA product label for KYBELLA (deoxycholic acid) injection. (accessed via FDA labeling database; specific supplemental history not reproduced here).

DrugChatter Q&A for KYBELLA

Can a rn buy kybella 2025?
When does kybella come off patent protection?